EGFR-Targeted Therapy Alters the Tumor Microenvironment In EGFR-Driven Lung Tumors: Rationale for Combination Therapies

被引：0
|
作者：
Jia, Y. [1 ]
Jiang, T. [1 ]
Li, X. [1 ]
Zhao, C. [1 ]
Zhou, C. [1 ]
Zhao, S. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
lung cancer; EGFR-TKI; tumor microenvironment;
D O I：
10.1016/j.jtho.2018.08.554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA27.10
引用
收藏
页码：S457 / S457
页数：1
相关论文
共 50 条
  • [31] The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma
    Li, Yuan-Yuan
    Lam, Sze-Kwan
    Zheng, Chun-Yan
    Ho, James Chung-Man
    JOURNAL OF CANCER, 2015, 6 (04): : 382 - 386
  • [32] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
    Akbay, Esra A.
    Koyama, Shohei
    Carretero, Julian
    Altabef, Abigail
    Tchaicha, Jeremy H.
    Christensen, Camilla L.
    Mikse, Oliver R.
    Cherniack, Andrew D.
    Beauchamp, Ellen M.
    Pugh, Trevor J.
    Wilkerson, Matthew D.
    Fecci, Peter E.
    Butaney, Mohit
    Reibel, Jacob B.
    Soucheray, Margaret
    Cohoon, Travis J.
    Janne, Pasi A.
    Meyerson, Matthew
    Hayes, D. Neil
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Hammerman, Peter S.
    Dranoff, Glenn
    Wong, Kwok-Kin
    CANCER DISCOVERY, 2013, 3 (12) : 1355 - 1363
  • [33] Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy
    Okamoto, Isamu
    FEBS JOURNAL, 2010, 277 (02) : 309 - 315
  • [34] Circulating Tumor DNA for Noninvasive Monitoring of Non-Small Cell Lung Cancer Patients Receiving EGFR-Targeted Therapies
    Tsui, Dana
    Muhammed, Murtaza
    Wong, Alvin S. C.
    Rueda, Oscar M.
    Forshew, Tim
    Soo, Ross
    Wong, H. I.
    Goh, Boon Cher
    Eisen, Tim
    Marass, Francesco
    Gale, Davina
    Liu, Wei
    Chin, Tan Min
    Rosenfeld, Nitzan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S358 - S359
  • [35] EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
    Venugopalan, Abhilash
    Lee, Min-Jung
    Niu, Gang
    Medina-Echeverz, Jose
    Tomita, Yusuke
    Lizak, Martin J.
    Cultraro, Constance M.
    Simpson, Robert Mark
    Chen, Xiaoyuan
    Trepel, Jane B.
    Guha, Udayan
    ONCOTARGET, 2016, 7 (34) : 54137 - 54156
  • [36] Metabolic approach to EGFR-targeted therapy in non-small cell lung cancer
    Kam, Yoonseok
    Swain, Pamela
    Romero, Natalia
    Dranka, Brian P.
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Establishment, Characterization and in Vivo Evaluation of Preclinical Tumor Models to Elucidate Differential Response to EGFR-targeted Therapies
    Wick, M.
    Vaught, T.
    Thangasamy, A.
    Meade, J.
    Tolcher, A.
    Patnaik, A.
    Smith, L.
    Drengler, R.
    White, A. J.
    Papadopoulos, K.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 57 - 57
  • [38] NOVEL COMBINATION OF CYTOTOXIC AGENTS FOLLOWED BY EGFR-TARGETED MAINTENANCE THERAPY FOR RECURRENT NASOPHARYNGEAL CARCINOMA
    Kaylani, Samer Zaid
    Parsons, Kerry
    Pressey, Joseph
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S76 - S76
  • [39] Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
    Akbay, Esra A.
    Koyama, Shohei
    Carretero, Julian
    Altabef, Abigail
    Tchaicha, Jeremy
    Christensen, Camilla
    Shimamura, Takeshi
    Shoii, Lynette
    Rodig, Scott
    Freeman, Gordon
    Hammerman, Peter
    Dranoff, Glenn
    Wong, Kwok-Kin
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [40] Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy
    Fisk, J. Nicholas
    Gaffney, Stephen
    Politi, Katerina
    Gettinger, Scott
    de Miguel, Fernando
    Townsend, Jeffrey
    CANCER RESEARCH, 2023, 83 (07)
12345